Optimizing Early-Stage Autologous Cell Therapy Processes to Enable Future Commercial Scale-Out & Manufacturing Feasibility
- Implementing early-stage process optimization strategies across cost, manufacturing complexity, and regulatory considerations to establish foundations for commercial viability
- Addressing critical decisions during early development that impact future scale-out capabilities, from producing 10 doses in phase one to thousands in commercial manufacturing
- Balancing multiple optimization workstreams, including out-of-spec reduction and process simplification during early phases to prevent costly late-stage manufacturing bottlenecks